Psychedelic Stocks

2020-10-06 PSW Editor

Noted psychedelic drug expert, Hamilton Morris, is the latest addition to Mind Cure's advisory board.

2020-10-05 Jeff Nielson

Field Trip Psychedelics is targeting a $16 billion treatment market with its ketamine-assisted psychotherapy clinics.

2020-10-05 PSW Editor

This is MindMed's first step in establishing a Center for Psychedelic Medicine at NYU Langone Health.

2020-10-01 Jeff Nielson

Dr. Dan Engle, a leading voice in psychedelic medicine, has been appointed by Mind Cure (CSE:MCUR) as a scientific advisor

2020-09-29 PSW Editor

Mind Cure's new Chief Operating Officer has already launched several successful businesses.

2020-09-29 PSW Editor

Field Trip announces testing of its first synthesized psychedelics molecule.

2020-09-29 PSW Editor

Mind Cure's new Chief Operating Officer has already launched several successful businesses.

2020-09-29 PSW Reporter

The company bolsters its executive team with the addition of an industry leader and experienced entrepreneur

2020-09-28 Jeff Nielson

With trading volumes going through the roof and a potential NASDAQ listing, will MindMed be the next billion-dollar psychedelics company?

2020-09-25 PSW Editor

Kevin O’Leary won’t touch cannabis as an investment but he loves the potential of psychedelic drugs. Why?

2020-09-25 PSW Editor

Mydecine Innovation's Mindleap subsidary launches a telehealth platform for psychedelics.

2020-09-25 Jeff Nielson

Psychedelic stocks have exploded on news of the Compass Pathways IPO. Three companies are leading the charge.